ESWT or Extracorporeal ShockWave Therapy produces sound waves with a very specific waveform eliciting a strong cellular response. The sudden change in pressure caused by the shockwaves triggers the cells to respond as it would to trauma, increasing your healing time by up to 20x.

The sound waves are pulsed onto the body directly where your indication is located using a hand-held device that is pain-free. This results in the opening of existing blood vessels and the growth of new ones as well. It additionally stimulates cellular tissue repair resulting in better improved and increased healing times.

Numerous studies show the release of:

- Growth factors

- Anti-inflammatory agents

- Improved blood supply in response to ESWT

SoftWave TRT Company History

Tissue Regeneration Technologies, LLC (hereinafter referred to as “TRT”) is a limited liability company based in Woodstock, Georgia. It was founded in 2004 as SoftWave Technical Service, LLC, and amended its name to its current form in 2006. TRT is a medical technology company that develops, manufactures, and sells SoftWave devices used to treat a variety of medical conditions. Originally conceived and operated as a research and development company, TRT began marketing and sales operations of its products in 2008. TRT is currently engaged in business throughout the United States, and has a strong international presence through its German affiliate, MTS Europe GmbH (hereinafter referred to as “MTS”).
TRT develops and manufactures its “Softwave” devices through its German affiliate, MTS. The technology utilized in the devices can be categorized into two groups:

• Patented, unfocused SoftWaves for soft tissue indications (e.g., wounds)
• Focused SoftWave for lithotripsy and bone indications (e.g., non-healing fractures).

The patented “SoftWave” technology uses various lens configurations to produce pressure waves. These waves have a characteristic pressure profile of short rise-times reaching high amplitudes (comparable to a sonic boom). The pressure waves can be shaped through a reflector, which enables the transmission of either highly-focused SoftWave for use on urinary stones or non-union fractures, or soft-focused pressure waves (i.e., SoftWaves) for most soft tissue indications.
TRT’s patented SoftWave technology is distinguished from competitors’ shockwave technology in that TRT uses a patented parabolic (as opposed to an ellipsoid) reflector in the therapy head, which allows delivery of unfocused waves of acoustic energy over a broad target area. TRT’s SoftWave technology generates less pain, has a higher efficacy rate, and has a lower re-treatment rate than competitors’ high-energy, focused shockwave systems. TRT is the first company to discover that SoftWaves have the same or better clinical benefit as high energy focused shockwaves for most medical conditions. Following this discovery, TRT further developed the idea into a useful format, and secured patents protecting its inventions.
The advantages of SoftWave technology include the following benefits:

• treatments do not require anesthesia
• larger surfaces, such as wounds, can be treated faster and easier than with competing shockwave devices
• SoftWave devices can be manufactured to be smaller and less expensive than competing shockwave devices, alleviating the need for a costly field service organization.